Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Files An 8-K Other Events
Item8.01. Other Events.
On April3, 2017, Tetraphase Pharmaceuticals,Inc. (the Company),
issued a press release announcing completion of enrollment in
IGNITE4, its ongoing phase 3 clinical trial evaluating the
efficacy and safety of intravenous eravacycline compared to
meropenem in complicated intra-abdominal infections. The Company
expects to report top-line data from this trial in the third
quarter of 2017.
A copy of the press release announcing these events has been
filed as Exhibit99.1 to this Current Report on Form8-K and is
incorporated herein by reference.
Item9.01. Financial Statements and Exhibits.
| (d) | Exhibits |
See Exhibit Index attached hereto.
About Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)
Tetraphase Pharmaceuticals, Inc. (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections. It has developed eravacycline using its chemistry technology. The Company’s TP-271 is a fully synthetic spectrum preclinical compound that the Company developed for respiratory diseases caused by bacterial biothreat pathogens. The Company created TP-271 using its chemistry technology. In its development program for TP-271, the Company has conducted a number of in vitro, toxicology and animal studies to evaluate the efficacy of TP-271 against biothreat pathogens. It also develops TP-6076 for multidrug-resistant Gram- negative infections. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Recent Trading Information
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) closed its last trading session up +0.09 at 9.28 with 1,145,145 shares trading hands.